Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
Hélène Haguet, Jonathan Douxfils, C Chatelain, et al.
TH Open (2018) Vol. 02, Iss. 01, pp. e68-e88
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Synthesis of Novel Nilotinib Analogues and Biological Evaluation of Their Antiplatelet Activity and Functionality towards Cancer Cell Proliferation In Vitro
L. Pechlivani, Nikoleta Ntemou, Despoina Pantazi, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 349-349
Open Access | Times Cited: 6
Genetic associations of plasma proteins and breast cancer identify potential therapeutic drug candidates
Liuliu Quan, Xin Luo, Chenxu Meng, et al.
Communications Biology (2025) Vol. 8, Iss. 1
Open Access
The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study
Hélène Haguet, Céline Bouvy, Anne-Sophie Delvigne, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 29
Exploiting polypharmacology to dissect host kinases and kinase inhibitors that modulate endothelial barrier integrity
Selasi Dankwa, Mary-Margaret Dols, Ling Wei, et al.
Cell chemical biology (2021) Vol. 28, Iss. 12, pp. 1679-1692.e4
Open Access | Times Cited: 16
Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors
Yihua Wang, Richard Travers, Alanna Farrell, et al.
PLoS ONE (2023) Vol. 18, Iss. 11, pp. e0294438-e0294438
Open Access | Times Cited: 6
Cancer Therapies and Vascular Toxicities
Alexandra Meilhac, Jennifer Cautela, Franck Thuny
Current Treatment Options in Oncology (2022) Vol. 23, Iss. 3, pp. 333-347
Closed Access | Times Cited: 8
Ponatinib Induces a Procoagulant Phenotype in Human Coronary Endothelial Cells via Inducing Apoptosis
Bálint Krajcsir, Marianna Pócsi, Zsolt Fejes, et al.
Pharmaceutics (2024) Vol. 16, Iss. 4, pp. 559-559
Open Access | Times Cited: 1
Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia: A Population-Based, Propensity Score-Matched Cohort Study
Mei-Tsen Chen, Shih‐Tsung Huang, Chih‐Wan Lin, et al.
The Oncologist (2021) Vol. 26, Iss. 11, pp. 974-982
Open Access | Times Cited: 9
Hypertension in Cardio-Oncology Clinic: an update on etiology, assessment, and management
Amir Askarinejad, Azin Alizadehasl, Amir Ghaffari Jolfayi, et al.
Cardio-Oncology (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 3
Acute coronary syndromes in cancer patients
Irma Bisceglia, Maria Laura Canale, Chiara Lestuzzi, et al.
Journal of Cardiovascular Medicine (2020) Vol. 21, Iss. 12, pp. 944-952
Closed Access | Times Cited: 6
High‐grade B‐cell lymphoma developed during the treatment of chronic myeloid leukemia with bosutinib
Teruhito Takakuwa, Ryota Sakai, Shiro Koh, et al.
Clinical Case Reports (2021) Vol. 9, Iss. 3, pp. 1344-1349
Open Access | Times Cited: 6
Impact of Tyrosine Kinase Inhibitors Applied for First-Line Chronic Myeloid Leukemia Treatment on Platelet Function in Whole Blood of Healthy Volunteers In Vitro
Falk Eckart, Josephine T. Tauer, Meinolf Suttorp, et al.
Hämostaseologie (2023) Vol. 43, Iss. 03, pp. 179-187
Open Access | Times Cited: 2
Endothelial function measured by peripheral arterial tonometry in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy: a pilot study
Tomohiro Kaneko, Sakiko Miyazaki, Azusa Kurita, et al.
Cardio-Oncology (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 2
Cardiovascular Events throughout the Disease Course in Chronic Myeloid Leukaemia Patients Treated with Tyrosine Kinase Inhibitors—A Single-Centre Retrospective Study
Andreea Varga, Ioan Ţilea, Dorina Nastasia Petra, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 10, pp. 3269-3269
Open Access | Times Cited: 5
Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH–SETH
José Ramón González‐Porras, José Mateo, Verónica González‐Calle, et al.
Clinical & Translational Oncology (2021) Vol. 24, Iss. 5, pp. 770-783
Closed Access | Times Cited: 5
ROCK and Rolling Towards Predicting BCR-ABL Kinase Inhibitor-Induced Vascular Toxicity
Jenica N. Upshaw, Richard Travers, Iris Z. Jaffe
JACC CardioOncology (2022) Vol. 4, Iss. 3, pp. 384-386
Open Access | Times Cited: 3
Microbubble-based liposomal delivery of dasatinib and COL11A1siRNA for enhanced combination therapy against lung adenocarcinoma
Mahalakshmi Nannan, V. Sivaramakrishnan
Applied Nanoscience (2024)
Closed Access
Endothelium as a Source of Cardiovascular Toxicity From Antitumor Kinase Inhibitors
Richard Travers, Alec Stepanian, Iris Z. Jaffe
Arteriosclerosis Thrombosis and Vascular Biology (2024) Vol. 44, Iss. 10, pp. 2143-2153
Closed Access
Isolated pulmonary vasculitis associated with nilotinib use: A case report
Nicolette T. Morris, Mihaela Taylor, Melkon Hacobian, et al.
Leukemia Research Reports (2020) Vol. 14, pp. 100214-100214
Open Access | Times Cited: 3
An ultra-long circulating nanoparticle for reviving a highly selective BCR-ABL inhibitor in long-term effective and safe treatment of chronic myeloid leukemia
Liyi Fu, Fengming Zou, Qingwang Liu, et al.
Nanomedicine Nanotechnology Biology and Medicine (2020) Vol. 29, pp. 102283-102283
Closed Access | Times Cited: 3
Comment on “Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk”
Carlos Antonio Moura, Fabiana Santos Rosa, Luiz Henrique de Assis, et al.
Drugs & Aging (2021) Vol. 38, Iss. 6, pp. 535-537
Open Access | Times Cited: 1
Predictive value of clinical examination parameters for cardiovascular adverse events during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors
Mika Nakamae, Hirohisa Nakamae, Mika Hashimoto, et al.
International Journal of Hematology (2021) Vol. 115, Iss. 3, pp. 329-335
Closed Access | Times Cited: 1
BOSUTINIB IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA: A LITERATURE REVIEW OF ITS IMPACT ON THE CARDIOVASCULAR SYSTEM
Sabina G. Cherenova
Bulletin of Medical Science (2023) Vol. 29, Iss. 1, pp. 141-146
Open Access
Heart Failure and Malignancy: Implications of Chemotherapy and Radiation in the Pathogenesis of Cardiomyopathy in Cancer Treated Populations
Samy I. McFarlane
Journal of Cardiology & Cardiovascular Therapy (2020) Vol. 16, Iss. 4
Open Access
High grade B-cell lymphoma developed in the course of chronic myeloid leukemia treatment with bosutinib
Teruhito Takakuwa, Ryota Sakai, Shiro Koh, et al.
Authorea (Authorea) (2020)
Open Access
Page 1 - Next Page

Scroll to top